ECS Botanics has secured an exclusive licence from California-based breeding group Terphogz to manufacture and sell its medicinal cannabis range in Germany, Australia and New Zealand.
Under the eight-year deal, the range will launch in Germany under a B2B model and in Australia through a new, direct-to-consumer, channel. The most appropriate channel for New Zealand has yet to be determined.
Terphogz owns a genetic library known for creating some of the most sought-after strains in the industry, including the award-winning ‘The Original Z’.
ECS told the ASX the agreement leverages its cultivation capabilities, licensed GMP facilities and global reach – along with Terphogz genetics, product portfolio, and brand – “to provide patients access to genetics and products previously limited to Californian medical and recreational markets”.
Managing director Nan-Maree Schoerie added: “We are delighted to partner with Terphogz to bring The Original Z and other unique Terphogz products to a global market.
“The recent regulatory change in Germany provides a great opportunity to introduce the Terphogz GMP-certified products to patients, providing them access to one of the world’s most iconic cannabis brands, with the assurance that it is produced under stringent quality standards.
“This partnership enables ECS to provide German, Australian and New Zealand patients access to high-quality medicinal cannabis with the unique Z terpene profiles and associated therapeutic benefits.”
Terphogz managing director Jon Orantes added: “We are so thrilled to have organically found a partner in ECS, who also cultivate organically to the highest standards, with living soil, just as our patients and followers have come to expect from us stateside.
“Most importantly, we really like the team at ECS, some of whom we have known for many years, making this a great opportunity for us, as well as patients in emerging markets worldwide, to taste the strains.”